CPRX CATALYST PHARMACEUTICALS, INC.
FY2025 10-K
CATALYST PHARMACEUTICALS, INC. (CPRX) filed its fiscal year 2025 10-K annual report with the SEC on Feb 25, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Pharmaceutical development and commercialization, primarily focused on therapies for rare neuromuscular diseases
- • New emphasis: $200 million share repurchase program initiated October 2025, aimed at returning capital to shareholders
Management Discussion & Analysis
- • Revenue $589.0M in 2025, up $97.3M YoY from $491.7M; net product revenue $588.8M vs $489.3M, driven by AGAMREE® launch and FIRDAPSE® volume growth
- • Operating margin implied by net income $214.3M (up from $163.9M) on revenues $589.0M, net income margin ~36.4% vs ~33.3% in 2024
Risk Factors
- • Paragraph IV litigation with Hetero USA on FIRDAPSE® patents expiring 2032–2037, trial scheduled March 23, 2026
- • Exposure to Most Favored Nation pricing proposals under GUARD and GLOBE Medicare projects, impacting realized drug sale prices
Financial SummaryXBRL
Revenue
$589M
Net Income
$214M
Operating Margin
43.8%
Net Margin
36.4%
ROE
22.5%
Total Assets
$1.1B
EPS (Diluted)
$1.68
Operating Cash Flow
$209M
Source: XBRL data from CATALYST PHARMACEUTICALS, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on CATALYST PHARMACEUTICALS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.